

Alexandra Voutsina

Associate Researcher
Institute of Chemical Biology (ICB)
National Hellenic Research Foundation (NHRF)
Phone: +30 210 7273741
E-mail: voutsina@eie.gr
Orcid: <https://orcid.org/0000-0002-8132-2348>
Google Scholar: [Alexandra Voutsina - Google Scholar](#)
Website: www.eie.gr



APPOINTMENTS

- 2022 -2023** Research Assistant Professor, "*Clinical applications of -omic technologies in disease prognosis and prediction of therapeutic outcome*", Institute of Chemical Biology, National Hellenic Research Foundation
- 2019-2021** Postdoctoral Researcher, Greek Genome Center, Biomedical Research Foundation of the Academy of Athens
- 2016 -2018** Postdoctoral Researcher, Laboratory of Translational Oncology, Medical School, University of Crete
- 2005-2015** Postdoctoral Researcher, Laboratory of Tumor Biology, Medical School, University of Crete
- 1998-2004** Postdoctoral Researcher, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas

RECENT RESEARCH ACTIVITIES

Tumor Heterogeneity in Lung, Breast and Colon Cancer as a Determinant of Therapeutic Resistance

Unraveling the Role of Homologous Recombination Repair Deficiency in Treatment Decisions in NSCLC

Characterization of the Molecular Features Leading in Resistance to EGFR and Immune Check Point Inhibitors in NSCLC

Development of Liquid Biopsy Diagnostic Tools for the Detection of Minimal Residual Disease

Development of NGS Assays to Analyze Tissue, Circulating Tumor Cells and Plasma cell-free DNA (cfDNA)

SELECTED PUBLICATIONS

1. Prognostic Value of KRAS Mutations in Colorectal Cancer Patients, Koulouridi A, Karagianni M, Messaritakis I, Sfakianaki M, **Voutsina A**, Trypaki M, Bachlitzanaki M, Koustas E, Karamouzis MV, Ntavatzikos A, Koumarianou A, Androulakis N, Mavroudis D, Tzardi M, Souglakos J, *Cancers*, 14, (2022) doi:10.3390/cancers14143320, <http://www.ncbi.nlm.nih.gov/pubmed/35884381>.
2. Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity, Kanaki Z, **Voutsina A**, Markou A, Pateras IS, Potaris K, Avgeris M, Makrythanasis P, Athanasiadis EI, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulas V, Kotsakis A, Klinakis A, *Cancers*, 13, (2021) doi:10.3390/cancers13102446, <http://www.ncbi.nlm.nih.gov/pubmed/34070013>.
3. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer, Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, **Voutsina A**, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G, *Clin Colorectal Cancer*, 17, e631-e637, (2018) doi:10.1016/j.clcc.2018.06.003, <http://www.ncbi.nlm.nih.gov/pubmed/29980490>.
4. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment, Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, **Voutsina A**, Psyrris A, Georgoulas V, Lianidou E, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 24, 1500-1510, (2018) doi:10.1158/1078-0432.CCR-17-1181, <http://www.ncbi.nlm.nih.gov/pubmed/29284708>.
5. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer, Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, **Voutsina A**, Sotiriou A, Athanasakis E, Xynos E, Mavroudis D, Tzardi M, Souglakos J, *PLoS One*, 13, e0197327, (2018) doi:10.1371/journal.pone.0197327, <http://www.ncbi.nlm.nih.gov/pubmed/29883450>.
6. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors, Koinis F, **Voutsina A**, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulas V, Kotsakis A, *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, 20, 140-149, (2018) doi:10.1007/s12094-017-1702-6, <http://www.ncbi.nlm.nih.gov/pubmed/28631135>.
7. Detection of K RAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer, Matikas A, **Voutsina A**, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulas V, *Transl Oncol*, 10, 693-698, (2017) doi:10.1016/j.tranon.2017.06.005, <http://www.ncbi.nlm.nih.gov/pubmed/28692881>.
8. Role of circulating free DNA in colorectal cancer, Matikas A, **Voutsina A**, Trypaki M, Georgoulas V, *World J Gastrointest Oncol*, 8, 810-818, (2016) doi:10.4251/wjgo.v8.i12.810, <http://www.ncbi.nlm.nih.gov/pubmed/28035251>.

9. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer, Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, **Voutsina A**, Koutsopoulos A, Mavroudis D, Georgoulas V, Souglakos J, Br J Cancer, 111, 1757-1764, (2014b) doi:10.1038/bjc.2014.492, <http://www.ncbi.nlm.nih.gov/pubmed/25233397>.
10. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer, Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulas V, **Voutsina A**, PLoS One, 9, e104902, (2014) doi:10.1371/journal.pone.0104902, <http://www.ncbi.nlm.nih.gov/pubmed/25137394>.
11. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer, **Voutsina A**, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulas V, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 26, 302-313, (2013) doi:10.1038/modpathol.2012.150, <http://www.ncbi.nlm.nih.gov/pubmed/22936063>
12. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome, Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, **Voutsina A**, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J, PLoS One, 8, e84604, (2013) doi:10.1371/journal.pone.0084604, <http://www.ncbi.nlm.nih.gov/pubmed/24367680>.
13. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC, Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulas V, Mavroudis D, **Voutsina A**, Br J Cancer, 99, 923-929, (2008) doi:10.1038/sj.bjc.6604629, <http://www.ncbi.nlm.nih.gov/pubmed/19238633>.

SELECTED CONFERENCES/WORKSHOPS

1. HRD status of patients with early stage Non Small Cell Lung Cancer, 2023 ASCO, Annual Meeting, June 2-6 2023, Chicago, IL, USA
2. Studying tumor heterogeneity of primary non-small cell lung cancer in humans and mice (PDX), European Lung Cancer Virtual Congress, 24 Mar 2021
3. Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer ASCO, June 2-6 2017, Chicago, IL, USA
4. Next generation sequencing identifies actionable mutations in EGFR-wild type and KRAS mutant non-small cell lung cancer patients ESMO Congress, 7-11 October 2016, Copenhagen, Denmark
5. Long term clinical benefit of EGFR wt in advanced NSCLC patients treated for long time with salvage erlotinib. A retrospective analysis. 16th World Conference on Lung Cancer (WCLC). September 6 - 9 2015, Denver, Colorado, USA
6. Basics in human genetic diagnostics. A course for CGLGs, The Cyprus Institute of Neurology and Genetics, Cyprus 20-24. June 2016

PARTICIPATION IN SELECTED FUNDED RESEARCH PROJECTS

	Project Title	Funding source
2020	B-PREIMMUN, Immunological and molecular biomarkers in peripheral blood for cancer patient selection towards chemotherapy	Operational Program «Competitiveness and Entrepreneurship» (OPCE II) and the new Operational Program Competitiveness, Entrepreneurship & Innovation – EPAnEK
2016	Incidence of Non-Small Cell Lung Cancer (NSCLC) in Crete during the period 2003-2014 and prospective evaluation of the clinical practice for the molecular characterization of the disease	Novartis
2016	Characterization of the molecular changes leading in resistance to 3rd generation EGFR-TKIs in patients with EGFRmut NSCLC using liquid biopsy	Astra Zeneca
2015	CATCH-U-DNA “Capturing non-Amplified Tumor Circulating DNA with Ultrasound Hydrodynamics”	EU FET-open
2014	“Intratour heterogeneity, clonal selection and metastatic propensity in breast cancer”	ERA-NET: Aligning national/regional translational cancer research programs and activities TRANSCAN-2
2007	“OncoSeed Diagnostics: Biology of Circulating Tumour Cells, Distal Metastasis & Development of Liquid Biopsy Methods”	Cooperation, General Secretariat of Research and Technology of Greece

MEMBERSHIPS

2005 –2023 Member of Hellenic Oncology Research Group .

Member of Hellenic Society of Biochemistry and Molecular Biology

TEACHING ACTIVITIES

- 2023** Lecturer in Joint MSc Program: 'Oncology: from oncogenesis to therapy'; co-organized by ICB/NHRF and the Medical School, University of Crete, Greece.
- 2007 - 2018** Conducting 20% of the lectures for the course "Molecular Oncology". Optional course at the 5th Semester of studies at the Medical School of University of Crete
- 2011 - 2016** Preceptorship in Clinical and Translational Cancer Research Seminar for Medical, Surgical or Radiation Oncologists, Pathologists at the Department of Medical Oncology and the Laboratory of Tumor Biology, University of Crete
- 1998 - 2018** Conducting the lectures and supervising of the laboratory sessions for the courses "Genetics" and "Biotechnology". Compulsory courses at the 2nd and 5th Semester of studies at the Technological Educational Institution of Crete

SUPERVISION OF GRADUATE STUDENTS & POSTDOCTORAL FELLOWS

- 2018-** Ph.D Student (in progress): Chariklia Koutoulaki
University of Crete, laboratory of Tumor Biology
- 2014 - 2016** MSc Student: Anastasios Gkountakos
University of Crete, laboratory of Tumor Biology
- 2008 - 2014** Ph.D Student: Aristeia Kalykaki
University of Crete, laboratory of Tumor Biology
- 2001-2003** MSc Student: Kalliopi Gkouskou
University of Crete, Institute of Molecular Biology and Biotechnology